Steven Kelly

Steven Kelly is an experienced biotechnology executive with more than 30 years of leadership across oncology drug development, commercialization, and company building. Prior to joining Actithera, Steve served as President and CEO of Carisma Therapeutics, where he led the company’s evolution from an academic platform to a publicly traded, clinical-stage biotechnology company, raising more than […]

Andreas Goutopoulos

Dr. Andreas Goutopoulos founded Actithera with the vision of bringing medicinal chemistry-driven innovation to radioligand therapy. He has over 25 years of experience in drug discovery, including leadership roles at EMD Serono, where he directed the chemistry organization, and at M Ventures, where he served as Entrepreneur-in-Residence supporting company creation and scientific diligence. Andreas has […]

Darshan Dalal

Dr. Darshan Dalal is Chief Medical Officer at Actithera, where he leads the company’s clinical strategy and development organization as Actithera advances its next-generation radioligand therapy pipeline. He brings more than 15 years of global leadership experience across oncology, hematology, and radiopharmaceutical development, with a track record of advancing over 10 radioligands from preclinical research […]